Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About Us
    • AACR Journals
    • Subscriptions
    • Permissions & Reprints
    • Advertising
  • Article Collections
    • Focus Sections
    • Journal Collections
    • Hot Topics
    • "Best of" Collection
    • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Researchers Behind the Journals: Researcher Profiles
  • Alerts
    • Table of Contents
    • Editors' Picks
  • COVID-19
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Log in
  • My Cart

Search

  • Advanced search
American Association for Cancer Research

American Association for Cancer Research

Advanced Search

  • Home
  • About Us
    • AACR Journals
    • Subscriptions
    • Permissions & Reprints
    • Advertising
  • Article Collections
    • Focus Sections
    • Journal Collections
    • Hot Topics
    • "Best of" Collection
    • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Researchers Behind the Journals: Researcher Profiles
  • Alerts
    • Table of Contents
    • Editors' Picks
  • COVID-19
  • Visit AACR on Facebook
  • Follow AACR on Twitter
  • Visit AACR on LinkedIn
  • Visit AACR on YouTube

Researcher Bio - Charles G. Mullighan

Researchers Behind the Journals: Researcher Profile

Charles G. Mullighan

Blood Cancer Discovery, Scientific Editor

Author Profile: Charles G. Mullighan

Charles G. Mullighan, MBBS (Hons), MSc, MD, is the Deputy Director of the St. Jude Children’s Research Comprehensive Cancer Center. He joined the St. Jude Department of Pathology in 2008 and currently serves as co-leader of the Cancer Center’s Hematological Malignancies Program.

Dr. Mullighan’s research focuses on defining the landscape of genomic and epigenomic alterations that drive the pathogenesis of acute lymphoblastic leukemia (ALL) and related disorders and then using this information to develop experimental models that faithfully recapitulate the genetics of human ALL. He has led landmark studies that have profoundly influenced our understanding of genetic basis of ALL and have led to novel diagnostic and therapeutic approaches and multiple clinical trials. In 2018, Dr. Mullighan established the Public Resource of Patient-derived and Expanded Leukemias, or PROPEL, initiative. This initiative makes available to the scientific community one of the world’s largest collections of clinically and genetically characterized xenograft leukemia samples from children and adults.

Dr. Mullighan has been an active member of the American Association for Cancer Research (AACR) since 2004 and is currently serving as a Scientific Editor for Blood Cancer Discovery. He has received numerous honors, including the National Cancer Institute R35 Outstanding Investigator Award (2017) and the American Association for Cancer Research Team Science Award (2009).

  • Mutational Landscape and Patterns of Clonal Evolution in Relapsed Pediatric Acute Lymphoblastic Leukemia
    Waanders E…Mullighan CG. Blood Cancer Discovery January 2020.
  • Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma
    Wei X…Chen S. Cancer Research May 2018.
  • Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia
    Diaz-Flores E…Kim KL. Cancer Research May 2019.
  • Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia
    Kannan S…Shelley M. Molecular Cancer Therapeutics September 2019.
  • OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL
    Evans K…Pritchard T. Clinical Cancer Research July 2019.

Back to top


American Association for Cancer Research
615 Chestnut Street  |  17th Floor  |  Philadelphia, PA 19106-4404
Phone: (215) 440-9300  |  Fax: (215) 440-9354  |  E-mail:  pubs@aacr.org

  • Home
  • Alerts
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Article Collections

  • Focus Selections
  • "Best of" Collection

Info for:

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

AACR Journals

  • About AACR Journals
  • 3rd Party Permissions & Reprints
AACR logo

Copyright © 2021 by the American Association for Cancer Research.